PACLITAXEL (paclitaxel) by Teva is protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. Approved for breast cancer after failure of combination chemotherapy for metastatic disease, relapse within 6 months of adjuvant chemotherapy, breast cancer and 3 more indications. First approved in 2002.
Drug data last refreshed 10h ago
Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of…
Worked on PACLITAXEL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo